1 The EIC Accelerator Project

The EIC Accelerator program, a flagship initiative of the European Innovation Council, aims to support small and medium-sized enterprises (SMEs) and startups in their quest for innovation and growth. This program primarily focuses on deep tech and high-risk, high-potential projects that can significantly impact the European economy. The EIC Accelerator provides a blend of funding options, including grants and equity investments, to foster the development and commercialization of breakthrough technologies.

Funding Structure

Under the EIC Accelerator program, companies can receive substantial financial support through a blended finance model. This includes:

Purpose and Impact

The EIC Accelerator serves as a vital component of the European DeepTech and startup ecosystem. It aims to bridge the funding gap often faced by innovative companies, particularly in the early stages of development when traditional financing options may be limited. By providing significant financial support, the EIC Accelerator encourages entrepreneurship, enhances competitiveness, and fosters collaboration among startups, corporates, and research institutions.

Moreover, the program plays a pivotal role in helping companies scale by offering not only financial resources but also access to a network of mentors, industry experts, and potential partners. This support is essential for navigating the complex landscape of innovation, commercialization, and market entry.

Case Study: Healium Medical

Company Overview

Healium Medical, based in Israel, is a winner of the EIC Accelerator program. The company specializes in advanced medical technologies, focusing on improving patient outcomes through innovative solutions.

Project Overview: DMUT

Healium Medical's project, titled DMUT (Dual-Mode Ultrasound Technology), aims to revolutionize the treatment of Atrial Fibrillation (AF), a common heart condition characterized by irregular heartbeat. The DMUT project introduces an easy-to-use, contactless ultrasound technology designed to enhance the accuracy of AF treatments.

Technology Basics and Background

The DMUT technology combines two modes of ultrasound to provide non-invasive treatment options for patients suffering from Atrial Fibrillation. Traditional methods for treating AF often involve invasive procedures, which can carry risks and require lengthy recovery times. Healium Medical's innovative approach focuses on contactless treatment, utilizing advanced imaging and therapeutic techniques to improve patient safety and comfort.

The core technology behind DMUT involves the integration of high-frequency ultrasound waves that can accurately target and ablate cardiac tissues responsible for irregular heart rhythms. By employing dual-mode functionality, the system enhances precision in identifying affected areas, thereby increasing treatment efficacy. This capability not only aims to improve clinical outcomes but also seeks to reduce the overall burden on healthcare systems.

The significance of DMUT lies in its potential to democratize access to advanced cardiac care, making it easier for healthcare providers to implement effective AF treatments. By simplifying the treatment process and minimizing invasiveness, Healium Medical hopes to set a new standard in the management of Atrial Fibrillation, ultimately leading to better health outcomes for patients.

In conclusion, the EIC Accelerator program plays a critical role in nurturing innovative projects like Healium Medical's DMUT, providing essential funding and support to help transform groundbreaking ideas into viable market solutions. The program's commitment to fostering deep tech innovation is instrumental in driving economic growth and enhancing the quality of healthcare across Europe and beyond.

2 The Funding Rounds

Healium Medical: Financing and Funding Overview Since EIC Accelerator Award (October 2021)

Financing Raised

• Total disclosed funding for Healium Medical stands at approximately $18.75 million as of March 2024.
• The company received a €2.5 million (~$2.9M) grant from the European Innovation Council (EIC) as part of the Accelerator program in October 2021.

Funding Rounds: Timing and Amounts

• Three funding rounds have been reported:
• The most recent round raised $10.25 million, though the exact date is not specified, it is noted as "last funding" on financial trackers updated in March 2024.
• Another recorded round was an Incubator/Accelerator round for $10,000 ($0.01M) closed on December 8, 2023.
• Prior to these rounds, the EIC Accelerator award (€2.5m) served as a significant non-dilutive grant in October 2021.

Investor Information

• At least two named investors participated across three total funding rounds; however, their identities are not publicly disclosed in available databases specific to Healium Medical.
• Market data platforms confirm multiple investors but do not provide detailed breakdowns or names beyond institutional references such as the EIC grantor.

Valuations

Market capitalization and specific company valuations remain undisclosed as of all recent reporting periods through early 2024.

Exit Events (IPO/Buyout/Acquisition)

• No public records exist indicating that Healium Medical has undergone an IPO, buyout, or acquisition event since receiving its EIC Accelerator award.
• There are no announcements or filings regarding exits up to April 24, 2025.

Summary Table

Date	Event/Funding Round	Amount Raised	Key Investors
Oct 6, 2021	EIC Accelerator Grant	€2.5M (~$2.9M)	European Innovation Council
Dec 8, 2023†	Incubator/Accelerator II	$10K	Not Disclosed
Mar(?) 2024‡	Series A (?)	$10.25M	Not Disclosed

</em>Date of Step II submission; grant likely awarded soon after
†Round details confirmed by CB Insights
‡Date inferred from latest data update

Additional Funding Context

Healium Medical’s current fundraising targets include a Series A round aiming for an additional $4 million with a closing date listed at March 31st, 2025—indicating ongoing capital raising efforts at present. No additional information about close dates or participation levels is available.

No exit events have taken place since their major EU innovation win.

---

Sources

• Healium Medical Financials - Startup Nation Finder
• Healium Medical Stock Price & Funding History – CB Insights
• Healium Medical Company Information & Investors – Techleap Finder
• Healium Medical Company Profile – Startup Luxembourg Directory
• Dealroom – Healium Medical Profile

3 The Press Releases

Healium Medical, an Israeli company, received the EIC Accelerator funding in October 2021. However, specific details about the funding and its immediate impact on Healium Medical are not readily available in the provided search results. Here is the information available about Healium Medical since then:

Company Overview

Healium Medical is a medical device startup focused on developing innovative technologies for cardiovascular interventions. They have been recognized for their non-contact guided ablation system, which won the prestigious ICI 2019 Innovation Award for its treatment of atrial fibrillation. This system uses ultrasound technology to achieve rapid, non-contact circumferential pulmonary vein isolation with real-time lesion monitoring, addressing key limitations in current ablation methods.

Technology Advancements

The company's solutions include the use of piezo ultrasound elements for its ablation technology, which plays a crucial role in the new treatment method. Healium Medical's approach aims to improve procedure efficacy, simplify procedure flow, and shorten procedure time by leveraging ultrasound energy for precise lesion formation around the pulmonary veins.

Partnerships

While there are no specific mentions of new partnerships since the EIC funding, Healium Medical has been involved in competitions and accelerators. It was named one of 24 startups in the MedTech Innovator Asia Pacific accelerator program in 2023, indicating its continued engagement with the medical technology innovation ecosystem.

Press Releases and Updates

Healium Medical's updates often focus on its participation in industry events and competitions. For instance, it attended the MedTech Innovator meeting and Wilson Sonsini conference in 2023, highlighting its commitment to networking within the medical technology community. However, there are no recent press releases on their website specifically discussing the EIC Accelerator funding or its aftermath.

Other Healium Entities

It's worth noting that there are other companies named Healium involved in different sectors, such as virtual reality and chronic kidney disease detection, but these are distinct from Healium Medical.

Sources: - Healium Medical Blog

• Healium Medical Blog Page 2
• Healium Medical Receives ICI 2019 Innovation Award
• Healium Medical Won the 1st Prize of the ICI 2019 Innovation Award

4 The Technology Advancements

Healium Medical, an Israeli medical technology company, specializes in advanced miniaturized ultrasound-guided therapeutic technology aimed at simplifying the rapidly growing market of ablation procedures. The company operates from Yokneam, Israel, and its team includes medical technology engineers and ultrasound physicists with extensive experience in developing ultrasound systems and transcatheter medical devices for cardiology applications.

Since receiving the EIC Accelerator funding on October 6, 2021, there is limited publicly available detailed information specifically documenting Healium Medical's advancements or improvements directly attributable to this funding. However, based on their stated focus and expertise:

• Current Capabilities: Healium develops image-guided ultrasound ablation technologies intended to enhance precision in therapeutic interventions such as cardiac ablations. Their core competency lies in miniaturizing ultrasound devices that can be used for guided therapy within cardiology.
• Technological Improvements or New Features: No explicit public disclosures have been found detailing new features or significant upgrades post-EIC funding submission. There are no identified patents filed by Healium recently nor new scientific publications or whitepapers released publicly that detail technological advancements since late 2021.
• Market Demonstrations (Customers/Pilots/Clinical Trials): There is no specific evidence of clinical trials or pilot program announcements involving Healium’s technology since obtaining the EIC support. No public case studies or demonstrations with customers have been reported.
• Intellectual Property and Scientific Output: Searches did not reveal any newly filed patents by Healium Medical following their EIC Accelerator award date nor any recent scientific studies published under their name related to their ablation technologies.

In summary, while Healium Medical continues to position itself as a specialized player in miniaturized ultrasound-guided ablation therapies within cardiology—leveraging experienced engineering talent—the publicly accessible information does not document visible progress such as new product features, market deployments (clinical trials/pilots), patent filings, or scientific publications explicitly after October 2021 when they received EIC Accelerator funding. It may indicate ongoing development work typical for early-stage medtech companies but without widely public updates so far.

Sources: - Healium Medical | Image-Guided Ultrasound Ablation

About | Healium Medical | Medical technology

5 The Partnerships and Customers

Healium Medical, an Israel-based innovator in ultrasound-guided therapeutic solutions, has strategically expanded its partnerships and customer base since receiving EIC Accelerator funding in October 2021. These collaborations aim to enhance its technological capabilities and market presence in minimally invasive ablation therapies.

Key Partnerships

• Broncus Holding Corporation (2022): Healium entered a strategic cooperation agreement to integrate Broncus’s energy ablation technologies with its own ultrasound-guided systems, likely targeting pulmonary or airway-related interventions.
• Venus Medtech (Joint Venture - 2021): Established Renaly Ltd. with Venus Medtech to develop next-generation renal denervation (RDN) devices for hypertension treatment. This partnership leverages Healium’s ultrasound ablation expertise and Venus’s structural heart device commercialization experience.

Customer Base

Healium’s core customers include healthcare institutions requiring advanced ablation solutions, though specific post-2021 client acquisitions are not publicly detailed. Prior clients focused on image-guided therapeutic applications consistent with Healium’s specialization in miniaturized ultrasound systems.

Market Positioning & Strategic Impact

• Technology Synergies: The Venus Medtech joint venture directly enhances Healium’s cardiovascular portfolio by combining ultrasonic ablation with catheter-based delivery systems, positioning it as a contender in the $10B+ hypertension device market.
• Scaling Through Collaboration: Integration of Broncus’s energy modalities suggests cross-platform compatibility improvements, potentially reducing procedural complexity for multi-therapy clinical settings.

Future Trajectory

These relationships enable access to Asia-Pacific markets through Venus Medtech while consolidating Healium's role as a provider of modular ablation technologies adaptable to diverse clinical needs—key factors for scaling amid growing demand for outpatient image-guided therapies.

---

Sources

• HEALIUM MEDICAL ENTERS INTO STRATEGIC COOPERATION AGREEMENT WITH BRONCUS HOLDING CORPORATION
• Venus Medtech introduces new-generation RDN products

6 The Hiring and Company Growth

Healium Medical: Team Growth and Hiring

Healium Medical, an Israeli company specializing in image-guided ultrasound ablation, received EIC Accelerator funding in October 2021. Since then, the company has been actively growing and expanding its team.

Current Headcount and Team Size

While the exact current headcount is not publicly disclosed, Healium Medical is described as an early-stage company with a multidisciplinary team, including medical technology engineers and ultrasound physicists. This suggests a team structure focused on innovation and development.

Hiring and Job Openings

Healium Medical is actively hiring and invites potential candidates to join their team. They have listed open positions on their website, though specific titles are not detailed publicly. The company's focus on developing complex medical technologies indicates a need for skilled professionals in fields like engineering and software development.

Growth and Scaling

The company's growth is underscored by its technological advancements and recognition in the medical field, such as winning the ICI 2019 Innovation award. New team members are crucial for scaling the company, as they bring expertise necessary for further development and commercialization of Healium Medical's innovative ultrasound ablation technology.

Management and Founding Team

Ran Sela serves as the Co-Founder and CEO, bringing extensive experience in medical device development, particularly in cardiology. Roman Lerman is the Software Manager, with a background in full-stack development. These leadership roles highlight a strong foundation in both technology and management, which is vital for the company's future growth.

Impact of New Team Members

New team members will play a significant role in enhancing Healium Medical's capabilities in research and development, product innovation, and market expansion. Their contributions will be essential in scaling the company's operations and advancing its position in the medical technology sector.

Major Changes in Management

There is no publicly available information regarding recent changes in the management or founding team of Healium Medical.

Sources

• Healium Medical
• Healium Medical Careers
• Healium Medical About Us

7 The Media Features and Publications

Healium Medical, an Israeli company that won the EIC Accelerator funding in October 2021, has garnered media attention and participated in various industry events since then. Below is a detailed overview of their media features, publications mentioning them, podcast or interview appearances by their team, as well as conference participations and event involvement.

Media Features and Publications

Healium Medical has been featured primarily in medical technology news platforms and industry-specific conferences. Key content about the company highlights its innovation in ultrasound-guided ablation therapy using Dual-Mode Ultrasound Technology (DMUT), which allows non-contact continuous tissue ablation with real-time monitoring. Additionally, Healium's mental wellness app has received updates covered on their official blog detailing enhancements like a personalized data dashboard for tracking brain patterns and heart rates during sessions.

While there are no large mainstream news outlets listed explicitly naming Healium Medical from these sources, industry-specific coverage such as Life Science Intelligence’s Emerging Medtech Summit positioned the company prominently within medtech circles.

Podcasts and Interviews

There is no direct evidence from the search results of specific podcasts or interviews featuring Healium Medical’s team members discussing their technology. However:

• The "Resonance" podcast by Baylor College of Medicine focuses on showcasing scientific advancements but does not explicitly mention Healium Medical episodes.
• General medical podcasts recommended for healthcare providers do not specifically list episodes with Healium representatives but include relevant themes around digital health innovations where such companies might be discussed indirectly.

Therefore, while there may be indirect or pending opportunities for interviews or podcast guest appearances related to digital health innovations including companies like Healium Medical, no confirmed public interviews or podcasts featuring their team were found.

Conference Visits, Presentations & Event Participation

Healium Medical actively participates in medtech conferences to present its advancements:

• At LSI USA 2023 Emerging Medtech Summit held recently (video available on YouTube), Ran Sela presented Healium’s novel atrial fibrillation treatment technology focusing on precise non-contact ablation with lesion monitoring capabilities.
• They also planned participation at LSI Europe 2023 in Barcelona later that year as part of expanding international exposure within life sciences events.

These engagements highlight the company's commitment to sharing its technological breakthroughs directly with stakeholders including investors and clinical professionals at specialized summits.

Involvement in Events

Beyond presentations at summits such as LSI USA '23 and upcoming LSI Europe '23 events mentioned above:

• No additional specific event sponsorships or broader community involvements were referenced.
• Their online presence includes active promotion of product releases (such as app updates) through blogs which serve as informal event-like announcements engaging users digitally worldwide.

---

Summary

Since securing EIC Accelerator funding in October 2021:

• Healium Medical has been featured mainly through specialized medtech summit presentations spotlighting innovative ultrasound technologies.
• They maintain an active content strategy via blogs explaining product improvements enhancing user experience.
• Their leadership presented at major medtech meetings like LSI USA ‘23 with plans for further European summits.

No direct mentions were found regarding popular media publications naming them broadly nor confirmed podcast/interview appearances by team members up to this date.

---

Sources

• About | Healium Medical
• Healium Medical Official Website
• Everything You Need to Know About Our Biggest Update Ever | TryHealium Blog
• Ran Sela Presents Healium Medical at LSI USA '23 - YouTube
• 25 Medical Podcasts Healthcare Providers Should Listen To | OpenLoop Health
• 43 Best Medical Podcasts to Listen to in 2024 | Intrepy